All In Biotech

Investigational drug · Phase 3

Claseprubart

Also called: DNTH103

Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Myasthenia Gravis, Generalized, Chronic Inflammatory Demyelinating Polyneuropathy, Multifocal Motor Neuropathy.

Phase 3

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

4

4 still active

All registered trials

4

Any phase or sponsor naming "Claseprubart"

First trial start

2024

Feb 23, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Claseprubart", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Myasthenia Gravis, Generalized
  • Chronic Inflammatory Demyelinating Polyneuropathy
  • Multifocal Motor Neuropathy

Approved drugs for the same conditions: Myasthenia gravis · Neurology

Largest trials

Live from ClinicalTrials.gov: studies naming "Claseprubart" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Myasthenia Gravis, Generalized

  • TelitaciceptRC18, RC18-LPhase 38 trials

    RemeGen Co., Ltd. · CTD-ILD, Primary Sjogren's Disease, Sjögren's Disease

  • PovetaciceptALPN-303Phase 37 trials

    Vertex Pharmaceuticals · Immunoglobulin A Nephropathy, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy

  • Descartes-08Phase 24 trials

    Cartesian Therapeutics · Myasthenia Gravis, Generalized, Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV)

  • AritinerceptPhase 21 trial

    Aurinia Pharmaceuticals Inc. · Myasthenia Gravis, Generalized

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.